rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BCTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Stocks in play: BriaCell Therapeutics Corp.

      Announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients ...

      Oct 23Yahoo FinanceBCTX
      BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer

      Dynamic changes in PD-L1 expression on circulating cancer-associated macrophage-like cells (CAML) were significantly associated with progression-free survival and overall survival following immunotherapies including the BriaCell regimenFindings from a prospective pooled analysis of 111 heavily pretreated metastatic breast cancer patients support further evaluation of circulating CAML PD-L1 as a potential biomarker of clinical benefit from immunotherapiesPooled analysis includes patients from mul

      Oct 23Yahoo FinanceBCTX
      Stocks in play: BriaCell Therapeutics Corp.

      Today announced that four abstracts featuring preclinical research from their respective immunotherapy ...

      Oct 6Yahoo FinanceBCTX
      BriaCell phase 3 breast cancer study gets seventh DSMB approval
      Sep 14Investing.comBCTX
      Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

      Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitorSeventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy approachPhase 3 study is being conducted under FDA Fast Track designation, underscoring the substantial unmet need in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOB

      Sep 14Yahoo FinanceBCTX
      Stocks in play: BriaCell Therapeutics Corp.

      Detailed price information for Briacell Therapeutics Corp (BCT-T) from The Globe and Mail including charting and trades.

      Sep 14The Globe and MailBCTX
      BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

      Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as “Eleven clinical trials that will shape medicine in 2026” PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering C

      Sep 8Yahoo FinanceBCTX
      BriaCell Shares Turn Volatile After Melanoma Vaccine Development Milestone

      BriaCell Therapeutics (NASDAQ:BCTX) shares experienced a volatile session on Monday after the biotechnology company announced that its Bria-MEL+ melanoma vaccine candidate had reached an important genetic engineering milestone. The stock initially jumped 25% following the announcement before surrendering those gains later in the session, highlighting the market’s shifting reaction to the development-stage programme.

      Aug 24Yahoo FinanceBCTX
      BriaCell stock choppy on melanoma vaccine milestone
      Aug 24Investing.comBCTX
      BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™

      Cell-based immunotherapy program is designed to harness patients’ own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturingProgram builds on BriaCell’s experience in metastatic breast cancer and prostate cancer, further expanding its therapeutic vaccine platform Melanoma remains a significant unmet medical need, with approximately 112,000 new cases and 8,510 deaths expected in t

      Aug 24Yahoo FinanceBCTX

      This is the newest page. Registered accounts read further back.